Physician profile
Hongwei Wang
NPI 1639468267
$1,507.24
in general payments reported to CMS, 2019-2025
11 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $74.12 · 2022: $158 · 2023: $109 · 2024: $289 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $524.02 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $221.06 | 2023-2024 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $209.70 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $203.70 | 2021-2023 | |
| Gilead Sciences, INC. | $137.31 | 2019-2021 | |
| Novo Nordisk INC | $69.88 | 2022-2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $53.56 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $35.26 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $18.51 | 2024 | Aptima |
| Vbi Vaccine (Delaware) INC. | $17.57 | 2023 | Prehevbrio |
| Novartis Pharmaceuticals Corporation | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongwei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.